title: Reply: GDNF poses troubling questions for doctors, drug maker.
authors.forename: John T
authors.initials: JT
authors.lastname: Slevin
authors.forename: Greg A
authors.initials: GA
authors.lastname: Gerhardt
authors.forename: Charles D
authors.initials: CD
authors.lastname: Smith
authors.forename: Don M
authors.initials: DM
authors.lastname: Gash
authors.forename: A Byron
authors.initials: AB
authors.lastname: Young
mesh_terms: D002986:Clinical Trials as Topic; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000627:therapeutic use*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D012107:Research Design
chemical_list: D051100:Glial Cell Line-Derived Neurotrophic Factor